NSE filing, NSE: BETA. Summary written from the filing by ALFA Finder's alert engine.
Beta Drugs Ltd: key numbers
- Share price
- ₹1,849.70
- Market cap
- ₹2,051 Cr
- Revenue (annual)
- ₹384.8 Cr
- Net profit (annual)
- ₹41.48 Cr
- P/E (TTM)
- 39.5×Sector 48.7×
- Promoter holding
- 58.91%-0.19% QoQ
- FII holding
- 1.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Beta Drugs Ltd
All →Beta Drugs Other Announcement
Beta Drugs Limited submitted its quarterly Statement of Deviation or Variation for the preferential issue proceeds, confirming no deviation from the stated objects.
Beta Drugs Earnings Call Transcript: Key Takeaways
Management projects a 20-25% growth trajectory despite Q2 bottlenecks. Recent acquisitions and niche oncology focus underpin expansion strategy.
- Call
- Guides 25% growth
Beta Drugs Investor Presentation: Key Takeaways
Beta Drugs reported H1 FY27 revenue of INR 263 Cr with EBITDA margins expanding to 23.2%. The firm is transitioning from a CMO to a branded specialty oncology powerhouse.
Beta Drugs Q2 FY27 Results: Net Profit ₹185,507,075 Cr, Up 51.8% YoY
Beta Drugs Ltd reported revenue from operations of ₹1,374,887,594 Cr (+33.0% YoY) and net profit of ₹185,507,075 Cr (+51.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹185,507,075 Cr · +51.8% YoY
Beta Drugs Board Meeting Date
Beta Drugs Limited notified the exchange of a board meeting scheduled for 22-Oct-2026 to consider quarterly financial results. The trading window closure was also intimated.
Beta Drugs Annual General Meeting
Beta Drugs Limited conducted its 21st Annual General Meeting on September 30, 2026. Shareholders considered resolutions including financial statement adoption, director re-appointments, and auditor ratification.
Other management change announcements
All →Western Overseas Study Abroad Management Change
Western Overseas Study Abroad Ltd disclosed that Non-Executive Director Mr. Deepak Kumar resigned effective 30 October 2026. The board will note the resignation, citing other work commitments.
Divgi Torqtransfer Systems Management Change
Divgi TorqTransfer Systems appointed Mr. Sarang Deshpande as Company Secretary and Compliance Officer. Ms. Ishita Kokare resigned that role effective October 30, 2026.
Religare Enterprises Management Change
Religare Enterprises appointed Ms. Dipti Jayesh Khandelwal as Company Secretary and Compliance Officer w.e.f. October 31, 2026. She was designated as a Key Managerial Personnel.
Amanta Healthcare Management Change
Amanta Healthcare's COO Shri Anil Rathi resigned effective October 29, 2026. The departure is disclosed under Regulation 30 of the SEBI Listing Regulations.
Mastek Management Change
Mastek Ltd appointed Mr. Niraj Khemka as Vice President – Finance. He will also lead Investor Relations for the company.
Bharat Road Network Management Change
Ms. Ankita Rathi has resigned from her position as Company Secretary and Compliance Officer of Bharat Road Network Limited, effective from October 29, 2026.